GlassScriptPhysician profile
Jennifer W Leiding
NPI 1053590273
$213,720.09
in general payments reported to CMS, 2019-2025
14 companies · $5,552 in 2025
The $5,552 reported for 2025 was more than what 81% of Pediatric Allergy/Immunology providers received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48K · 2020: $24K · 2021: $30K · 2022: $48K · 2023: $35K · 2024: $22K · 2025: $5,552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Consulting Fee: $18K · Travel and Lodging: $11K · Honoraria: $10K · Food and Beverage: $3,858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,700.00 |
| Consulting Fee | $18,178.85 |
| Travel and Lodging | $11,281.57 |
| Honoraria | $10,172.00 |
| Food and Beverage | $3,858.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $80,741.48 | 2021-2025 | |
| Horizon Therapeutics Plc | $74,889.98 | 2019-2023 | Actimmune |
| Csl Behring | $19,844.85 | 2019-2022 | |
| Grifols USA, LLC | $10,603.53 | 2023-2025 | Xembify, Gamunex-C |
| Amgen INC. | $9,111.07 | 2024-2025 | Actimmune |
| Pharming Healthcare, INC. | $8,270.90 | 2020-2024 | Ruconest |
| Takeda Pharmaceuticals U.S.A., INC. | $4,894.83 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $3,222.00 | 2022-2023 | |
| Grifols Shared Services North America, INC. | $1,532.78 | 2022-2025 | Xembify |
| Adma Biomanufacturing LLC | $328.11 | 2021-2024 | |
| Shire North American Group INC | $150.61 | 2019 | |
| Incyte Corporation | $68.11 | 2024 | |
| Genetix Biotherapeutics INC | $37.62 | 2024 | |
| Pfizer INC. | $24.22 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Leiding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.